Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23 | Free Publication Certificate
NAAS Rating: 5.23 new

Vol. 6, Issue 3 (2017)

Ranolazine: Antianginal medicine or more?

Sergiy Fedorov
Ranolazine, a piperazine derivative sold, is a well‐tolerated medication that selectively inhibits the late sodium current. It has beneficial metabolic properties and does not affect heart rate or blood pressure. Ranolazine is currently approved in the United States and Europe as a second‐line agent in the management of stable angina pectoris. In this review we showed that ranolazine is perspective medication for arrhythmia treatment.
Pages: 232-234  |  1038 Views  49 Downloads

The Pharma Innovation Journal
How to cite this article:
Sergiy Fedorov. Ranolazine: Antianginal medicine or more?. Pharma Innovation 2017;6(3):232-234.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal

Call for book chapter
The Pharma Innovation Journal